Although B-RAF inhibitors could be hypothetically used in N-RAS mutated melanoma to target the pathway downstream of N-RAS, vemurafenib causes paradoxical hyperactivation of MEK–ERK1/2 signaling, activates C-RAF, and promotes growth in mutant N-RAS cell lines [23,24]. The gene discussed is RAF1; the disease is melanoma.